Clinical Study

Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine

Emiliano Santarnecchi, Simone Rossi, Sabina Bartalini, Massimo Cincotta, Fabio Giovannelli, Elisa Tatti, and Monica Ulivelli

1Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, Brain Investigation & Neuromodulation Lab. (Si-BIN Lab), University of Siena, 53100 Siena, Italy
2Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Medical Center, Harvard Medical School, Boston, MA 02215, USA
3Unit of Neurology, Azienda Sanitaria di Firenze, 50121 Florence, Italy

Correspondence should be addressed to Emiliano Santarnecchi; esantarn@bidmc.harvard.edu

Received 1 March 2015; Accepted 17 June 2015

Academic Editor: Preston E. Garraghty

Copyright © 2015 Emiliano Santarnecchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In ten healthy subjects and in ten patients suffering from Multiple Sclerosis (MS), we investigated the cortical functional changes induced by a standard fatiguing repetitive tapping task. The Cortical Silent Period (CSP), an intracortical, mainly GABA B-mediated inhibitory phenomenon, was recorded by two different hand muscles, one acting as prime mover of the fatiguing index-thumb tapping task (First Dorsal Interosseous, FDI) and the other one not involved in the task but sharing largely overlapping central, spinal, and peripheral innervation (Abductor Digiti Minimi, ADM). At baseline, the CSP was shorter in patients than in controls. As fatigue developed, CSP changes involved both the “fatigued” FDI and the “unfatigued” ADM muscles, suggesting a cortical spread of central fatigue mechanisms. Chronic therapy with amantadine annulled differences in CSP duration between controls and patients, possibly through restoration of more physiological levels of intracortical inhibition in the motor cortex. These inhibitory changes correlated with the improvement of fatigue scales. The CSP may represent a suitable marker of neurophysiological mechanisms accounting for central fatigue generation either in controls or in MS patients, involving corticospinal neural pools supplying not only the fatigued muscle but also adjacent muscles sharing an overlapping cortical representation.

1. Introduction

Fatigue is intrinsic to Multiple Sclerosis (MS) and represents the most common symptom experienced by patients along the course of the disease [1], contributing to disability and to the worsening of their daily quality of life [2, 3]. It may originate at multiple levels of the nervous system “beginning with ideation of an activity within the cortex and ending with the process of muscle contraction and force generation” [4].

Such a biological complexity reflects the several, not mutually exclusive, mechanisms that have been invoked to explain the pathophysiology of fatigue in MS, altogether pointing to its central origin: (i) dysfunctions of inhibitory intracortical mechanisms [5, 6], (ii) increased corticomotor excitability [7], and (iii) impaired drive to the primary motor cortex (MI) [8], likely due to (iv) failure of motor programming upstream to pyramidal tracts [9], possibly because of (v) a less synchronous recruitment of corticospinal neurons [10]. Atrophy of cortical layers and white matter [11], reduced perfusion of grey nuclei at the subcortical level [12], diffuse axonal loss [13], and alterations of connectivity [14] may also contribute to generation of central fatigue.

Most of neurophysiological studies on fatigue used Transcranial Magnetic Stimulation (TMS) of the MI, since the amplitude of the motor evoked potential (MEP) directly reflects the excitatory corticospinal output drive [15, 16].
In these studies, results have been variable, since fatigue scales (Fatigue Severity Scale) [31] or scales measuring the impact of fatigue on quality of life (Fatigue Impact Scale) [32], also taking into account possible aggravating factors as diurnal sleepiness (Epworth Sleepiness Scale, ESS) [33]. (3) The third aim of the study is to verify the effects of chronic therapy of amantadine, one of the symptomatic therapeutic options for central fatigue [34, 35] in patients, both on CSP changes and on fatigue scales. Indeed, a recent pilot, randomized blind study suggested that amantadine, but not other symptomatic drugs such as Modafinil and acetyl-L-carnitine, significantly improved fatigue symptoms in patients with relapsing-remitting MS [36]. Several, still poorly known, mechanisms may potentially account for the beneficial effects of amantadine on fatigue: they include dopaminergic and glutamatergic actions, antiviral or immunologically mediated effect, and amphetamine-like activity [37]. Neurophysiological studies investigating effects of amantadine on central fatigue in MS are still lacking, although they may represent a valuable tool to elucidate some of these mechanisms.

### 2. Subjects and Methods

#### 2.1. Patients and Control Group
Ten right-handed female MS patients (mean age 35.9 years; SD 12.3, range 22–64 years) were finally selected from the clinical database of the Neurology and Clinical Neurophysiology Unit at Le Scotte Neurological Medical Center in Siena (Italy) (fifty consecutive patients were screened) and included in the study according to the following strict inclusion/exclusion criteria. Inclusion criteria were diagnosis of clinically defined MS [38], either with a relapsing-remitting (n = 8) or progressive (n = 2) course of the disease; Expanded Disability Status Scale (EDSS) [39] score ranging from 1 to 5.5 (mean EDSS in our sample = 2.1; SD 1.4), so that patients were fully able to perform the requested fatiguing task with their right hand; normal central conduction time, implying normal myelination and conductivity properties for corticospinal fibers directed to the right hand muscles. Five patients did not take long-term drugs; five patients were under treatment with β-interferon from more than three months (Table 1). Exclusion criteria were disease relapse in the last two months; presence of other

### Table 1: Demographics and clinical characteristics of MS patients.

<table>
<thead>
<tr>
<th>Sex, age</th>
<th>SM type</th>
<th>EDSS</th>
<th>Therapy</th>
<th>Dur.</th>
<th>Ham-A</th>
<th>Ham-D</th>
<th>Beck</th>
<th>FSS</th>
<th>FIS</th>
<th>ESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>F, 29</td>
<td>RR</td>
<td>1</td>
<td>No</td>
<td>—</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3.8</td>
</tr>
<tr>
<td>F, 43</td>
<td>RR</td>
<td>1.5</td>
<td>INFβ-1a (44 × 3)</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>6.4</td>
</tr>
<tr>
<td>F, 46</td>
<td>SP</td>
<td>3</td>
<td>No</td>
<td>—</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>3.6</td>
</tr>
<tr>
<td>F, 37</td>
<td>RR</td>
<td>1</td>
<td>No</td>
<td>—</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>6.2</td>
</tr>
<tr>
<td>F, 64</td>
<td>SP</td>
<td>5.5</td>
<td>INFβ-1b</td>
<td>15</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>6.4</td>
</tr>
<tr>
<td>F, 28</td>
<td>RR</td>
<td>1.5</td>
<td>INFβ-1a (44 × 3)</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>2.8</td>
</tr>
<tr>
<td>F, 22</td>
<td>RR</td>
<td>1</td>
<td>INFβ-1a (22 × 3)</td>
<td>24</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>F, 33</td>
<td>RR</td>
<td>2.5</td>
<td>No</td>
<td>—</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>5.8</td>
</tr>
<tr>
<td>F, 28</td>
<td>RR</td>
<td>1</td>
<td>No</td>
<td>—</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>8</td>
<td>7.2</td>
</tr>
<tr>
<td>F, 29</td>
<td>RR</td>
<td>2</td>
<td>INFβ-1a (44 × 3)</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>5.8</td>
</tr>
</tbody>
</table>

Mean 2.1
SD 1.4

*p < 0.05, Wilcoxon matched-pairs signed rank test.*
2.2. Fatiguing Task. We used a standard, easily and ecologically applicable motor task corresponding to the index-thumb tapping test, as defined in part-III of the Unified Parkinson’s Disease Rating Scale (UPDRS) [42]. In this task, the First Dorsal Interosseous (FDI) muscle acts as prime mover in conjunction with the flexors of the elbow, while the Abductor Digiti Minimi (ADM) muscle is not involved in task. However, both muscles share similar cortical representations [43, 44], myelomer, and the same peripheral ulnar nerve supply, so that the ADM appears as a suitable control for eventual spread of fatigue at cortical level.

Figure 1 depicts the entire protocol. In the same recording session, there were four fatiguing blocks, a pause of about 30 minutes, and additional four fatiguing blocks. Firstly, participants were requested to perform the index-thumb tapping consecutively for 60 seconds (MS patients) or 90 seconds (healthy subjects) (Post-1). At the end of each block, 5 CSP from one of the two muscles were recorded. The same procedure was repeated until 10 CSP from each muscle were obtained. In the second recording session (Post-2), carried out with the same timing of the first one and the same number of CSP per muscle, the tapping task lasted 90 seconds (MS patients) or 180 seconds (healthy controls). The different length of the fatiguing task in patients and controls allowed a comparable level of fatigue at the end of the task for the two groups, since the perceived effort during repeated contractions is higher in patients with MS [19]. Moreover, this prevented the possibility that patients wrongly performed the task at the end of the block due to excessive fatigue. The order of CSP recordings was randomized in both sessions.

2.3. Neurophysiological Protocol. Participants sat in a reclining chair, with their forearm resting on the armchairs. TMS of the dominant left motor cortex was produced using a Magstim 200 stimulator (Magstim Co., Whitland, Dyfed, UK) with an 8-shaped coil (external diameter of each loop = 9 cm). The coil handle was kept pointing backward and 45° away from the midline. Once the optimal spot for the right FDI and ADM had been defined, the coil position was marked on the scalp by an inking pen to ensure a correct repositioning during the experiment. The intervals between two consecutive TMS pulses were at least 7 seconds and differed pseudorandomly. Electromyographic signals were recorded through surface electrodes, placed in a belly-tendon montage on the right FDI and ADM muscles, by a four channel EMG system (bandpass 2–1,000 Hz, sampling rate 5 KHz). The ground electrode was positioned on the volar aspect of the forearm.
For CSP studies, analysis was carried out on 500 ms after-stimulus and 100 ms prestimulus windows. Firstly, we determined the resting motor threshold (RMT) according to a standard procedure [15, 40] searching for the minimal intensity eliciting MEPs with 50% probability in 1% increments of the TMS pulse intensity. For the CSP study, stimuli were delivered, while the subject performed a unilateral isometric contraction of the right target muscle (according to the order explained in the previous paragraph) at about 50% of maximum voluntary contraction. The CSP from the FDI and from the ADM was recorded separately (see Figure 1). Stimulus intensity was set at 120% of resting motor threshold (RMT) [45], which was repeatedly checked throughout the session. Since intraindividual CSP changes could merely reflect possible RMT modifications across the session, and due to the fact that the CSP duration could merely reflect possible RMT modifications across the session, and due to the fact that the CSP duration could merely reflect possible RMT changes, the CSP was also tested at stimulus intensity of 120% RMT as determined before the fatiguing task.

RMT repeatedly checked throughout the task (see Figure 1) changed neither in controls nor in patients, so these results are not reported. Single trials were rectified and averaged off-line and the resulting trace was used for measurements. The CSP duration was calculated from the negative peak of the MEP to the point when the post-MEP signal reached again 20% of the mean prestimulus EMG level [46]. CSP recordings were carried out in basal conditions and following the two progressively fatiguing tasks based on the index-thumb tapping with the timing described in the previous paragraph (see Figure 1). In the MS patients group, the whole neurophysiological protocol and clinical variables were again sampled after three months of therapy with amantadine 100 mg/die × 2 (see Figure 1).

2.4. Evaluation of Central Fatigue and Other Clinical Variables. At the beginning of each recording session before and after the treatment with amantadine, patients were requested to compile subjective scales measuring the severity of fatigue (Fatigue Severity Scale, FSS) [31], the impact of fatigue on the daily quality of life (Fatigue Impact Scale, FIS) [47], and the level of diurnal sleepiness (Epworth Sleepiness Scale, ESS) [33], another variable that could theoretically influence the level of central fatigue. With the aim of evaluating subthreshold depressive and anxiety symptoms, beyond exclusion criteria, we also administered the 14-item Hamilton scale for depression [48] (HAM-D), the 21-item Hamilton scale for anxiety [49] (HAM-A), and the Beck depression inventory [50] (BDI).

2.5. Data Analysis. Since the CSP from the FDI and ADM muscles were recorded separately (Figure 1), two separated repeated measures ANOVAs were conducted. A first analysis has been performed to evaluate differences in CSP duration between healthy controls and MS patients before amantadine treatment. Namely, CSP mean durations were entered in mixed ANOVAs with a repeated measures design, with Group (controls versus MS patients) as between-subjects factor and Session (3 levels: Baseline, Post-1, and Post-2) as within-subject factor. Then, in order to test the effect of the amantadine treatment on the CSP in MS patients, the dependent variable (i.e., CSP mean duration) was entered in two-way repeated measures ANOVAs with Session (3 levels: Baseline, Post-1, and Post-2) and Time (before and after the amantadine treatment) as within-subject factors. Finally, a mixed ANOVA has been used to compare MS patients after the amantadine treatment and healthy controls. To correct violations of the sphericity assumption, Greenhouse-Geisser corrections were applied when necessary. Post hoc tests were performed using paired t-test and Bonferroni correction for multiple comparisons. The level of significance for all tests was set at \( p < 0.05 \).

In MS patients, the variation of clinical scale scores before and after amantadine treatment was quantified by the Wilcoxon matched-pairs signed rank test. Correlations between percentage changes of FIS, FSS, and ESS scores with the percentage change of CSP duration in MS patients before and after treatment with amantadine were carried out using Spearman’s rho test.

3. Results

Figures 2 and 3 summarize results, which are herein described point-by-point according to the different questions addressed in the study.

3.1. Comparison between Healthy Controls and MS Patients without Treatment

3.1.1. FDI Muscle. No main effects of Group (\( F_{1,18} = 0.558, \ p = 0.465 \)) and Session (\( F_{2,36} = 1.930, \ p = 0.071 \)) were seen, whereas the interaction between these two factors was significant (\( F_{2,36} = 8.719, \ p = 0.002 \)). Post hoc comparisons revealed that the CSP recorded in MS patients before amantadine administration was significantly shorter than controls (mean ± SD: 120.3 ± 37.1 ms versus 156.6 ± 33.0 ms; Bonferroni-corrected alpha level: \( p = 0.033 \)), whereas no significant differences emerged after both fatiguing tasks (Figure 2). As for the healthy controls, CSP duration decreased after the fatiguing tasks with respect to the Baseline (mean ± SD: Post-1, 139.8 ± 40.9 and Post-2, 129.9 ± 40.1, Bonferroni-corrected alpha level for Post-1 and Post-2 conditions: \( p = 0.033 \) and \( p = 0.033 \), resp.). In contrast, an increase of CSP was observed in MS patients (mean ± SD: Post-1, 136.2 ± 44.1 and Post-2, 130.1 ± 51.0), although the effect reached significance only in the Post-1 condition (Bonferroni-corrected alpha level: \( p = 0.028 \)) (Figure 2).

3.1.2. ADM Muscle. No main effects of Group (\( F_{1,18} = 0.072, \ p = 0.792 \)) and Session (\( F_{2,36} = 0.050, \ p = 0.906 \)) were seen, whereas the interaction between these two factors was significant (\( F_{2,36} = 11.830, \ p = 0.001 \)). Post hoc comparisons revealed that, similarly to the results observed for the FDI muscle, in healthy controls CSP duration decreased after fatiguing tasks with respect to the Baseline, although the effect was significant only in the Post-2 condition.
Figure 2: Histograms represent the mean (± SE) duration of the cortical silent period (CSP) from the FDI muscle (a) and ADM muscle (b) in basal conditions and following two progressively fatiguing tasks (Post-1 and Post-2) both in controls and in MS patients before amantadine treatment. Statistics of the repeated measures ANOVA are reported in the text.

Figure 3: Histograms represent the mean (± SE) duration of the cortical silent period (CSP) from the FDI (a) and ADM (b) muscles at basal conditions and following two progressively fatiguing tasks (Post-1 and Post-2) recorded in MS patients before and after the amantadine treatment. Statistics of the repeated measures ANOVA are reported in the text.

3.2. Effects of Amantadine on the CSP in MS Patients

3.2.1. FDI Muscle. Before the amantadine treatment, the CSP duration was 120.3 ± 37.1 ms, 136.2 ± 44.1 ms, and 130.1 ± 51.0 ms for Baseline, Post-1, and Post-2 conditions, respectively. After the amantadine treatment, the CSP duration was 140.0 ± 36.4 ms, 138.5 ± 37.7 ms, and 144.2 ± 49.2 ms (Figure 3). Repeated measures ANOVA showed that the main effects of Session ($F_{2,18} = 1.836, p = 0.204$) and Time ($F_{1,9} = 0.775$, Bonferroni-corrected alpha level: $p = 0.038$) (Figure 2). In contrast, MS patients showed a significant increase of the CSP compared to the Baseline in the Post-2 condition (Bonferroni-corrected alpha level: $p = 0.049$) with a trend toward significance also for the Post-1 condition ($p = 0.053$) (Figure 2). At Baseline, the mean CSP duration in MS patients was shorter compared to healthy controls (mean ± SD: 121.6 ± 43.0 ms versus 147.5 ± 31.2 ms, resp.) but such difference did not reach statistical significance ($p = 0.141$) (Figure 2).
$p = 0.402$ and the interaction between these two factors ($F_{2,36} = 2.478, p = 0.112$) were not significant (Figure 3).

3.2.2. ADM Muscle. Before the amantadine treatment, the CSP duration was $121.6 \pm 43.0$ ms, $144.3 \pm 55.0$ ms, and $145.9 \pm 49.1$ ms for Baseline, Post-1, and Post-2 conditions, respectively. After the amantadine treatment, the CSP duration was $137.5 \pm 51.9$ ms, $124.8 \pm 44.9$ ms, and $117.2 \pm 39.8$ ms (Figure 3). The main effects of Session ($F_{1,9} = 0.373, p = 0.594$) and Time ($F_{2,36} = 0.609, p = 0.455$) were not significant, whereas the interaction between these two factors was significant ($F_{2,36} = 8.108, p = 0.016$) (Figure 3). Post hoc comparisons confirmed that before the amantadine treatment CSP duration was shorter for Baseline compared to Post-1 and Post-2 conditions (see results for the "comparison between healthy controls and MS patients without treatment" session), whereas after the amantadine treatment CSP did not differ across conditions. Moreover, no significant differences emerged between CSP durations recorded before and after the amantadine treatment for Baseline, Post-1, and Post-2 conditions.

Mixed ANOVA performed to compare MS patients under treatment with amantadine and healthy controls showed no significant differences in CSP duration for either the FDI and ADM muscles (Bonferroni-corrected alpha level: $p > 0.050$ for all comparisons).

3.3. Correlations between Clinical Scales and CSP Changes during Therapy. Fatigue scales improved in most of the patients (Table 1) after chronic therapy with amantadine: the improvement at the FSS was significant ($p = 0.012$), while the significance of the improvement at the FIS was marginal ($p = 0.059$). The ESS did not change significantly. Percentage changes of the CSP duration recorded from the FDI muscle in MS patients before and during chronic treatment with amantadine significantly correlated with improvement at the FIS scale ($p = 0.039, r = 0.673$) but not at the FSS and ESS scales. None of the correlations was significant for CSP changes in the ADM muscle.

4. Discussion

Results of the current study, the first-ever investigating the neurophysiological effects of amantadine on fatigue in MS patients, will be commented point-by-point in the following dedicated paragraphs.

4.1. Comparison between Healthy Controls and MS Patients without Treatment. The fatiguing exercise of a single hand muscle (i.e., index-thumb tapping according to the UPDRS-part III) induces, either in controls or in patients with MS, rapid adapting changes in the inhibitory circuits of the contralateral motor cortex or upstream to it, which spread to other muscles not involved in the fatiguing task (Figure 2). More in detail, the length of the CSP in controls progressively decreased according to the level of fatigue (Post-2 > Post-1), while in drug-free MS patients it increased at Post-1 and at Post-2 in both muscles, despite the fact that the ADM muscle was not engaged in the fatiguing task. At variance with short-interval intracortical inhibition changes, a measure of GABA$_A$ activity in the motor cortex [15], which were limited to the “fatigued” FDI muscle and spared the “unfatigued” ADM muscle [51], the presence of consistent CSP changes on both muscles suggests a spread of mechanisms generating fatigue at cortical level, where the neural populations controlling the FDI and ADM muscles are largely overlapping [43, 44]. Such a lack of selectivity of CSP adapting changes to the fatiguing exercise (which is in keeping with the notion that, as fatigue develops, there is a spread of muscle activation beyond the target muscle [51–53]) may plausibly account for the positive correlation of CSP changes with the improvement of subjective fatigue scales in patients whose scores would have been unlikely changed if fatigue would have influenced only one small hand muscle.

In previous studies on healthy subjects [51, 54, 55] or in MS patients with fatigue [19], changes in CSP duration were found to be confined to the fatigued muscle. However, these results are not comparable to the ones presented in this investigation, because CSP was recorded from tibialis anterior [54] or elbow flexors muscles [55] rather than from intrinsic hand muscles that, crucially, are supplied with monosynaptic corticospinal connections. Additionally, we looked at CSP changes occurring after the fatiguing task rather than during its execution [19, 51] for the following practical reasons: under these circumstances, (i) it is easier to keep a stable level of the isometric contraction preceding the TMS pulse and (ii) it is easier to balance the level of effort between controls and patients.

As fatigue developed (i.e., Post-2 > Post-1), there was an opposite trend of CSP duration in controls and in patients (Figure 2). Since the late part of the CSP would mainly reflect GABA$_A$-mediated mechanisms at the cortical level, disinhibition probably occurs at this level with prolonged tapping in healthy subjects. Indeed, both the repetitiveness of motor commands and sensory feedback signals from the contracting muscles are known to transiently reduce intracortical levels of GABAergic inhibition [56]. This could represent an adaptive process of inhibitory mechanisms at M1 and/or in different cortical and subcortical areas projecting to the MI, aiming at adapting corticospinal drive to the fatigued muscle(s) as well as a possible biological marker of central fatigue. Possibly, also the repetitive activation of group III-IV muscle afferents during sustained tapping might have influenced the responsiveness of the motor cortex to the TMS pulse in line with the notion that these afferents may facilitate central fatigue at least for endurance lower limb exercising [57].

Whatever the mechanism(s) generating central fatigue, it can be hypothesized that such a compensatory downregulation of inhibitory cortical mechanisms might be partly lost in MS patients, at least in the current sample which was selected on the basis of normal conductivity in corticospinal pathways towards the performing hand and with central fatigue. Under these circumstances, as fatigue develops, intracortical inhibitory circuits located within or upstream to MI might be engaged in an opposite manner. Notably, amantadine restored these adapting changes close to the level...
of those observed in control subjects (Figure 3) (see later in the discussion).

4.2. Differences between Patients and Controls “at Rest”. In basal conditions (i.e., before the fatiguing task), amantadine-free MS patients had a significantly shortened CSP in the FDI muscle than controls (Figure 2), which was in agreement with previous studies in which a shorter duration of the CSP was found in MS patients during disease relapse [57, 58]. In the current study, the chronic therapy with amantadine, which significantly improved scores of fatigue scales, produced a nonsignificant lengthening of the CSP that, however, annulled these differences between MS patients and controls. This indirectly suggests that the length of the CSP and its “responsiveness” to amantadine even before patients’ engagement in the fatiguing task, might represent a piece of the neurophysiological mosaic accounting for mechanisms generating motor fatigue at cortical level.

4.3. Effects of Amantadine on the CSP in MS Patients. Chronic therapy with amantadine improved central motor fatigue according to subjective measurements at FIS and FSS but not at the ESS. It also produced an increase of the CSP duration in patients when tested either before or after the fatiguing task, so that the significant difference between patients and controls at Baseline was annulled. The normalization of CSP duration induced by amantadine significantly correlated with the subjective perception of fatigue in the FDI muscle. Thus, CSP might be regarded as a suitable marker to neurophysiologically monitor the effects of symptomatic therapy for central fatigue. Amantadine, by its NMDA-antagonist mechanism [59], might have induced an increase in the physiological patterns of neural pools responsible for CSP possibly rebalancing the dysfunctional GABA/Glutamate levels at cortical level (i.e., M1 or upstream to M1) due to central fatigue. It is intriguing that amantadine was not able to change the duration of the CSP in normal subjects, at least during an acute challenge [60]. However, this could be due to a sort of ceiling effect in presence of a normal GABA/Glutamate balance. According to this hypothesis, a slight lengthening of CSP duration was seen in healthy volunteers after a single dose of dextromethorphan, another NMDA-antagonist [61].

A previous study documented the lack of CSP changes induced by chronic administration of Modafinil, another fatigue-modifying drug with a non-NMDA antagonism mechanism [62], despite improvement of subjective fatigue rating [63]. This, and other overall conflicting results on intracortical inhibitory and excitatory functions in MS patients with fatigue (see [64] for a review), might simply reflect that these results were obtained in patients with or without fatigue, while participants were “at rest” (i.e., not engaged in fatiguing motor tasks). This implies that eventual differences of cortical excitability due to fatigue should reflect a trait rather than a state. Therefore, testing patients “at rest” could have probably underestimated changes of neurophysiological variables induced by intercurring fatigue immediately after the motor task execution.

4.4. Limitations of the Study. The relatively small sample size and the lack of a placebo condition and of randomization are all factors limiting the strength of the conclusions. However, patients included in the current study were carefully selected according to very strict criteria. Objective neurophysiological measurements, as well as a persistent beneficial effect at three months, make the occurrence of possible placebo effects less likely. Moreover, half of the patients were under immunomodulating therapy with Interferon. A subanalysis of results did not show differences in CSP duration between treated and nontreated patients. However, larger samples of patients are needed to confirm this finding.

4.5. Conclusions. This is the first study addressing the neurophysiological effects of amantadine on central fatigue in MS patients. Results suggest that chronic treatment with amantadine restores more physiological levels of intracortical inhibition in the motor cortex in patients with MS, expressed as both a normalization of CSP in basal condition and a reduction of CSP duration after the fatiguing task, both associated to an improvement of central fatigue scores.

Interestingly, CSP may represent a suitable index of the neurophysiological mechanisms underpinning central fatigue in general, probably involving corticospinal neural pools directed not only towards the fatigued muscle but also towards adjacent muscles sharing an overlapping cortical representation.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Emiliano Santarnecchi and Simone Rossi contributed equally to the work.

References

[1] L. Krupp, “Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease,” *Multiple Sclerosis*, vol. 12, no. 4, pp. 367–368, 2006.


